3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
24
Breast Neoplasms
13
Uterine Cervical Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Pancreatic Neoplasms
9
Colorectal Neoplasms
9
Melanoma
8
Neoplasm Metastasis
6
Carcinoma, Ovarian Epithelial
6
Lung Neoplasms
5
Fallopian Tube Neoplasms
5
Vaginal Neoplasms
4
Urogenital Neoplasms
4
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Penile Neoplasms
4
Oropharyngeal Neoplasms
4
Anus Neoplasms
4
Vulvar Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Kidney Neoplasms
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Thyroid Carcinoma, Anaplastic
2
Testicular Neoplasms
2
Testicular Germ Cell Tumor
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Interventions
pembrolizumab
24
Paclitaxel
7
Docetaxel
7
Cyclophosphamide
7
Carboplatin
7
fludarabine
6
Taxes
6
Nivolumab
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
atezolizumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Gemcitabine
4
Fluorouracil
4
Cisplatin
4
tisotumab vedotin
3
fludarabine phosphate
3
Radiation
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Gene Expression Profiling
3
Drug Therapy
3
Counseling
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
aldesleukin
×
Gynecologic
×
Clear all
NCT02876510
2025-02-04
ACTolog
Immatics US, Inc.
Phase 1
Completed
38 enrolled